Cullinan Therapeutics, Inc.
CGEM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.04 | -1.86 | -0.24 |
| FCF Yield | 0.00% | -12.96% | -9.68% | -5.13% |
| EV / EBITDA | 1.84 | -4.92 | -6.76 | -11.51 |
| Quality | ||||
| ROIC | -12.28% | -15.35% | -9.93% | -9.31% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.73 | 0.82 | 0.89 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 35.92% | -33.49% | -17.83% | -7.28% |
| Safety | ||||
| Net Debt / EBITDA | 1.84 | 0.94 | 1.36 | 1.47 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -2,876.49 | -4,027.50 | -1,965.97 |